Sources & References
These references support the regulatory and educational context on this site. They do not endorse or promote any medicine, and listing a study does not mean a treatment is approved, effective or suitable for you. Research entries are labelled by evidence type only. Whether any treatment is appropriate is a decision for a registered doctor after an individual assessment.
Australian regulation
- Access pathways for unapproved therapeutic goods — Therapeutic Goods Administration (TGA) — Australian Government
- Special Access Scheme (SAS): Guidance for health practitioners accessing unapproved therapeutic goods — Therapeutic Goods Administration (TGA) — Australian Government
- Access to unapproved therapeutic goods for individual patients (Special Access Scheme) — Therapeutic Goods Administration (TGA) — Australian Government
- Access to unapproved therapeutic goods for multiple patients (Authorised Prescriber) — Therapeutic Goods Administration (TGA) — Australian Government
- Compounded medicines — Therapeutic Goods Administration (TGA) — Australian Government
- Manufacturing, supplying and advertising compounded medicines lawfully — Therapeutic Goods Administration (TGA) — Australian Government
- Personal Importation Scheme — Therapeutic Goods Administration (TGA) — Australian Government
- Prescription medicines — Therapeutic Goods Administration (TGA) — Australian Government
- Australian Register of Therapeutic Goods (ARTG) — Therapeutic Goods Administration (TGA) — Australian Government
- Advertising — Therapeutic Goods Administration (TGA) — Australian Government
- Safety alerts — Therapeutic Goods Administration (TGA) — Australian Government
- Therapeutic Goods Act 1989 — Australian Government — Federal Register of Legislation — 1989
- Register of practitioners — Ahpra — Australian Health Practitioner Regulation Agency
- Advertising hub — Ahpra — Australian Health Practitioner Regulation Agency
- How we regulate therapeutic peptide products — Therapeutic Goods Administration (TGA) — Australian Government
- Peptide product information for health practitioners — Therapeutic Goods Administration (TGA) — Australian Government
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products — Therapeutic Goods Administration (TGA) — Australian Government
- Prescribing off-label, unapproved or compounded medicines — Ahpra — Australian Health Practitioner Regulation Agency
Clinical guidelines & professional standards
- Telehealth consultations with patients — Medical Board of Australia — Medical Board of Australia
- Good medical practice: a code of conduct for doctors in Australia — Medical Board of Australia — Medical Board of Australia
- Guidelines for preventive activities in general practice (Red Book) — RACGP — Royal Australian College of General Practitioners
- The Prohibited List — World Anti-Doping Agency — WADA
Government health information
- Telehealth — Australian Government Department of Health, Disability and Ageing — health.gov.au
- Guide to blood testing — healthdirect — healthdirect Australia
- Buying medicines online — healthdirect — healthdirect Australia
- Medicines information — healthdirect — healthdirect Australia
- Peptides and your health in Australia: facts versus hype — healthdirect — healthdirect Australia
Peer-reviewed research
- Tirzepatide Once Weekly for the Treatment of Obesity — Jastreboff AM et al. — N Engl J Med — 2022 (Registered-medicine clinical trial)DOI
- Once-Weekly Semaglutide in Adults with Overweight or Obesity — Wilding JPH et al. — N Engl J Med — 2021 (Registered-medicine clinical trial)DOI
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — Jastreboff AM et al. — N Engl J Med — 2023 (Phase 2 trial of an investigational, unregistered compound)DOI
- BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing — Seiwerth S et al. — Curr Pharm Des — 2018 (Review of early animal and laboratory evidence)DOI
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Gwyer D et al. — Cell Tissue Res — 2019 (Review of early animal and laboratory evidence)DOI
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — Lee E et al. — Altern Ther Health Med — 2025 (Small pilot safety study)
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — McGuire FP et al. — Curr Rev Musculoskelet Med — 2025 (Narrative review)DOIFree full text (PMC)
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — Pickart L et al. — Int J Mol Sci — 2018 (Review of laboratory and gene-expression data)DOIFree full text (PMC)
- Ipamorelin, the first selective growth hormone secretagogue — Raun K et al. — Eur J Endocrinol — 1998 (Early animal and laboratory study)DOI
- Lee C et al. — Cell Metab — 2015 — Lee C et al. — Cell Metab — 2015 (Early animal and laboratory study)DOIFree full text (PMC)
See also our editorial standards. General information only, not medical advice.